Nintedanib in the treatment of idiopathic pulmonary fibrosis
Open Access
- 10 April 2015
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 9 (3) , 121-129
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease that occurs in older adults. The clinical course of IPF is variable and hard to predict in an individual patient. Nintedanib is a tyrosine kinase inhibitor that has recently been approved in the US and European Union for the treatment of IPF. Preclinical studies have shown that nintedanib interferes with processes active in fibrosis such as fibroblast proliferation, migration and differentiation and the secretion of extracellular matrix. The safety and efficacy of nintedanib have been investigated in the phase II TOMORROW trial and in two replicate 52-week randomized, placebo-controlled phase III trials known as the INPULSIS trials. These trials demonstrated that nintedanib slowed disease progression by reducing the annual rate of decline in forced vital capacity, with a manageable side-effect profile. In this review, we summarize key data supporting nintedanib as a treatment for patients with IPF and address key questions regarding the use of nintedanib in the clinical setting.Keywords
This publication has 24 references indexed in Scilit:
- Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosisRespiratory Research, 2014
- New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing ResponsesAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Staging of Acute Exacerbation in Patients with Idiopathic Pulmonary FibrosisLung, 2013
- Epidemiology of idiopathic pulmonary fibrosisClinical Epidemiology, 2013
- Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosisNature Genetics, 2013
- New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosisThe Lancet, 2012
- Comprehensive care of the patient with idiopathic pulmonary fibrosisCurrent Opinion in Pulmonary Medicine, 2011
- Idiopathic Pulmonary Fibrosis: Update on Genetic DiscoveriesProceedings of the American Thoracic Society, 2011
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor EfficacyCancer Research, 2008
- Acute Exacerbations of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007